Abstract
LY164846 is a semisynthetic arylglycyl cephalosporin which can be absorbed orally. It had in vitro activity comparable to that of cefaclor against beta-hemolytic streptococcal species and was two- to fourfold more active than cephalexin. Enterococci and Listeria species were resistant, and its activity against staphylococci was similar to that of other oral cephalosporins. Although some Bacteroides species were inhibited, the MICs for 25% were greater than or equal to 16 micrograms/ml. LY164846 was hydrolyzed by Staphylococcus aureus beta-lactamase and by cephalosporinases, but it was more stable than cefaclor.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology
Reference6 articles.
1. Comparison of in vitro activity of cephalexin, cephradine, and cefaclor;Bill N. J.;Antimicrob. Agents Chemother.,1977
2. Susceptibility of respiratory tract anaerobes to orally administered penicillins and cephalosporins;Busch D. F.;Antimicrob. Agents Chemother.,1976
3. Neu H. C. 1980. Antibiotic inactivating enzymes and bacterial resistance p. 454-473. In V. Lorian (ed.) Antibiotics in laboratory medicine. The Williams & Wilkins Co. Baltimore.
4. Cefaclor: in vitro spectrum of activity and beta-lactamase stability;Neu H. C.;Antimicrob. Agents Chemother.,1978
5. In vitro studies with cefaclor, a new oral cephalosporin;Sanders C. C.;Antimicrob. Agents Chemother.,1977
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献